Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026

Rhea-AI Summary

Lipocine (NASDAQ: LPCN) reported Q1 2026 results and a corporate update on May 7, 2026. The company had $24.7M in unrestricted cash and marketable securities at March 31, 2026, versus $14.9M at December 31, 2025. Net loss was $3.7M ($0.52/share).

In April 2026, Phase 3 topline results for oral brexanolone LPCN 1154 in postpartum depression did not meet the primary endpoint; the product was well tolerated and showed positive post hoc results in participants with a psychiatric history. Lipocine applied for breakthrough and fast track designations and is evaluating development and strategic options. TLANDO licensing and distribution agreements remain in place.

Positive

• Cash and marketable securities of $24.7M at March 31, 2026
• Post hoc Phase 3 subgroup (n=54) showed statistically significant HAM-D reductions
• Applied for breakthrough therapy and fast track designations for LPCN 1154
• Existing TLANDO licensing and distribution agreements across multiple territories

Negative

• Primary endpoint not met in Phase 3 LPCN 1154 trial for PPD
• Net loss widened to $3.7M in Q1 2026 from $1.9M year-ago (>10% change)
• R&D expenses increased to $2.8M in Q1 2026 from $1.1M in Q1 2025

News Market Reaction – LPCN

-0.84%

2 alerts

-0.84% Session close to close

+4.2% Peak Tracked

$20.06M Market Cap

0.1x Rel. Volume

In the May 8 session, LPCN declined 0.84%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement combines Q1 2026 financials with context around the recent LPCN 1154 Phase 3 outco...

Analysis

This announcement combines Q1 2026 financials with context around the recent LPCN 1154 Phase 3 outcome. Lipocine ended the quarter with $24.7M in cash, cash equivalents and marketable securities, offset by a wider net loss of $3.7M driven by higher R&D. TLANDO royalties grew to $119,000. Investors may watch future guidance on LPCN 1154’s path, additional licensing progress, and expense trends across R&D and G&A.

Key Figures

Cash & securities: $24.7M Prior cash balance: $14.9M Net loss: $3.7M +5 more

8 metrics

Cash & securities $24.7M Unrestricted cash, cash equivalents and marketable investment securities as of Mar 31, 2026

Prior cash balance $14.9M Unrestricted cash, cash equivalents and marketable investment securities at Dec 31, 2025

Net loss $3.7M Net loss for quarter ended Mar 31, 2026 (−$0.52 per diluted share)

Prior-year net loss $1.9M Net loss for quarter ended Mar 31, 2025 (−$0.35 per diluted share)

TLANDO royalties $119,000 Royalty revenue from TLANDO sales in quarter ended Mar 31, 2026 vs $94,000 in 2025

R&D expense $2.8M Research and development expenses for quarter ended Mar 31, 2026 (vs $1.1M in 2025)

G&A expense $1.2M General and administrative expenses for quarter ended Mar 31, 2026 (vs $1.1M in 2025)

Phase 3 sample size 90 patients N=90 in Phase 3 placebo-controlled trial of LPCN 1154 for postpartum depression

Previous Earnings Reports

5 past events · Latest: Mar 10 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Full-year 2025 earnings	Neutral	+2.9%	Reported 2025 results with $14.9M cash and $9.6M net loss.
Nov 06	Q3 2025 earnings	Neutral	+3.1%	Q3 2025 loss of $3.2M with ongoing LPCN 1154 Phase 3 progress.
Aug 05	Q2 2025 earnings	Neutral	-1.6%	Q2 2025 net loss $2.2M and TLANDO royalties plus license revenue.
May 08	Q1 2025 earnings	Negative	-2.0%	Q1 2025 swung to $1.9M loss and lower TLANDO royalties vs 2024.
Mar 13	Full-year 2024 earnings	Positive	+2.8%	2024 net income with $11.2M revenue largely from TLANDO licensing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent earnings releases have generally produced modest single‑digit percentage moves, with reactions tending to align with the tone of the updates.

Recent Company History

Over the past year, Lipocine’s earnings releases have combined liquidity updates with steady pipeline progress. Cash balances ranged from about $15.1M as of Sep 30, 2025 to $21.6M at Dec 31, 2024, while net results shifted from net income in 2024 to losses in 2025. TLANDO royalties and license revenues have been recurring themes. Today’s Q1 2026 report adds a higher cash position and wider loss alongside a pivotal LPCN 1154 Phase 3 miss already disclosed in April.

Key Terms

phase 3, placebo-controlled, ham-d, hamilton depression rating scale, +4 more

8 terms

phase 3 medical

"topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

placebo-controlled medical

"topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

ham-d medical

"reduction from baseline in HAM-D (Hamilton Depression Rating Scale) total score compared"

The HAM-D (Hamilton Depression Rating Scale) is a clinician-administered questionnaire that measures the severity of a person’s depressive symptoms and produces a single score used to track change over time. In clinical-trial and regulatory contexts, shifts in HAM-D scores indicate how well a treatment is working — like a thermometer for depression — so investors use those changes to judge a drug’s effectiveness, likely demand, and regulatory prospects.

hamilton depression rating scale medical

"in HAM-D (Hamilton Depression Rating Scale) total score compared to placebo at hour 60"

A clinician-administered questionnaire that rates the severity of a person’s depressive symptoms across mood, sleep, appetite and physical signs, producing a numeric score used to track change over time. Investors pay attention because these scores are often primary endpoints in clinical trials and can determine whether a treatment is seen as effective, influencing regulatory approval, prescribing use and the commercial value of mental-health therapies — like a standardized thermometer showing whether a treatment lowers the ‘fever’ of depression.

post hoc analysis medical

"In a post hoc analysis of participants with a history of psychiatric conditions (n=54)"

Post hoc analysis is an exploratory look at data carried out after a study or trial is finished to search for patterns or effects that were not specified beforehand. Because it’s done after seeing the results, findings can arise by chance and are less reliable than preplanned tests; investors should treat post hoc claims as hypothesis-generating signals that may need confirmatory studies or regulatory review before they meaningfully affect a company’s value.

breakthrough therapy regulatory

"has applied for breakthrough therapy and fast track designations for LPCN 1154 in PPD"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

fast track designations regulatory

"has applied for breakthrough therapy and fast track designations for LPCN 1154 in PPD"

A fast track designation is a regulatory status granted to a drug or therapy intended to treat a serious condition with unmet medical need, which gives the developer access to expedited interactions and review procedures with regulators. For investors, it’s like an express lane: it can shorten development and review timelines and reduce regulatory uncertainty, potentially speeding a product to market—but it does not guarantee approval or commercial success.

clinicaltrials.gov medical

"For more information on the Phase 3 trial, refer to clinicaltrials.gov: NCT06979544."

clinicaltrials.gov is a publicly accessible U.S. government database that lists details, timelines and status updates for medical studies testing drugs, devices or procedures. For investors it acts like a public calendar and scoreboard—showing when trials start, are delayed, or report results—so it helps gauge a company’s development progress, regulatory risk and potential value impact before official earnings or approvals are announced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2026 and provided a corporate update.

Neuroactive Steroids (NAS)

LPCN 1154 for Postpartum Depression ("PPD")

• In April 2026, Lipocine announced topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D (Hamilton Depression Rating Scale) total score compared to placebo at hour 60 in the full analysis set and the primary endpoint was not met.
• The Phase 3 results showed LPCN 1154 to be well tolerated, demonstrating a differentiated safety profile supportive of outpatient, at-home use, with no treatment-related serious adverse events, no cases of excessive sedation or loss of consciousness, and no treatment-related discontinuations.
• In a post hoc analysis of participants with a history of psychiatric conditions (n=54), LPCN 1154 showed statistically significant and clinically meaningful reductions in HAM-D scores versus placebo, observed as early as hour 12 and sustained through day 30.
• Based on these findings, Lipocine has applied for breakthrough therapy and fast track designations for LPCN 1154 in PPD and is awaiting FDA feedback.
• The Company intends to complete its full analysis of the Phase 3 trial data and plans to present results at upcoming medical conferences. For more information on the Phase 3 trial, refer to clinicaltrials.gov: NCT06979544.
• The Company is evaluating all options regarding the potential path forward for LPCN 1154. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol in patients with a history of psychiatric conditions, development of other product candidates, strategic transactions, partnerships, and other opportunities.

TLANDO^®

• Lipocine has an exclusive License Agreement with Verity Pharma, entered into in 2024, under which Verity Pharma has the rights to market TLANDO, its oral testosterone replacement therapy, in the United States and Canada, if approved.
• Lipocine has entered into additional license, supply and distribution agreements covering development and commercialization of TLANDO in other counties/ territories including Aché (Brazil), Pharmalink (GCC countries) and SPC (South Korea). 
• Lipocine continues to explore partnering TLANDO in territories outside the U.S., Canada, South Korea, the GCC countries, and Brazil.

First Quarter Ended March 31, 2026, Financial Results

As of March 31, 2026, Lipocine had $24.7 million of unrestricted cash, cash equivalents and marketable investment securities compared to $14.9 million at December 31, 2025.

Lipocine reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of $1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.

The company recognized royalty revenue from TLANDO sales of $119,000 during the quarter ended March 31, 2026, compared to royalty revenue of $94,000 during the quarter ended March 31, 2025.

Research and development expenses were $2.8 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase in research and development expenses was mainly the result of an increase in costs related to our LPCN 1154 clinical study in 2026.

General and administrative expenses were $1.2 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase in general and administrative expenses was primarily a result of an increase in various professional and consulting fees.

For further details on Lipocine's financial results for the quarter ended March 31, 2026, refer to Form 10-Q filed with the SEC.

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine's development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding the potential uses and benefits of products and product candidates, the commercial potential for product candidates, the timing of regulatory reviews and approvals and related procedures, and potential strategic opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
						March 31,		December 31,
						2026		2025
	Assets
Current assets:
	Cash and cash equivalents					$              5,015,608		$         5,205,842
	Marketable investment securities					19,713,463		9,724,545
	Accrued interest income					111,411		14,189
	License fee and royalties receivable					119,397		1,145,390
	Prepaid and other current assets					285,055		787,600
	Total current assets					25,244,934		16,877,566
Property and equipment, net of accumulated depreciation
of $1,298,893 and $1,284,079 respectively						89,479		104,293
Other assets						23,753		23,753
	Total assets					$            25,358,166		$       17,005,612
	Liabilities and Stockholders' Equity
Current liabilities:
	Accounts payable					$              1,562,728		$           971,822
	Accrued expenses					645,115		1,236,374
	Deferred revenue					320,000		320,000
	Total current liabilities					2,527,843		2,528,196
	Total liabilities					2,527,843		2,528,196
Stockholders' equity:
	Common stock, par value $0.0001 per share, 75,000,000
	shares authorized; 7,475,451 and 6,158,779 issued and
	7,475,115 and 6,158,443 outstanding, respectively					9,076		8,944
	Additional paid-in capital					235,937,414		223,901,106
	Treasury stock at cost, 336 shares					(40,712)		(40,712)
	Accumulated other comprehensive income					(7,194)		4,445
	Accumulated deficit					(213,068,261)		(209,396,367)
	Total stockholders' equity					22,830,323		14,477,416
	Total liabilities and stockholders' equity					$            25,358,166		$       17,005,612

 

LIPOCINE INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
						Three Months Ended March 31,
						2026		2025
Revenues:
	Royalty revenue					119,397		93,864
	Total revenues					119,397		93,864
Operating expenses:
	Research and development					2,764,394		1,061,571
	General and administrative					1,204,467		1,122,477
	Total operating expenses					3,968,861		2,184,048
	Operating loss					(3,849,464)		(2,090,184)
Other income:
	Interest and investment income					177,570		225,511
	Total other income					177,570		225,511
	Loss before income tax expense					(3,671,894)		(1,864,673)
Income tax expense						-		(200)
Net loss attributable to common shareholders						$          (3,671,894)		$         (1,864,873)
Basic loss per share attributable to common stock						$                  (0.54)		$                 (0.35)
Weighted average common shares outstanding, basic						6,795,002		5,348,557
Diluted loss per share attributable to common stock						$                  (0.54)		$                 (0.35)
Weighted average common shares outstanding, diluted						6,795,002		5,348,557
Comprehensive loss:
	Net loss					$          (3,671,894)		$         (1,864,873)
	Net unrealized loss on marketable investment securities					(11,639)		(3,617)
	Comprehensive loss					$          (3,683,533)		$         (1,868,490)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2026-302766140.html

SOURCE Lipocine Inc.

FAQ

What were Lipocine's Q1 2026 cash and liquidity figures (LPCN)?

Lipocine reported $24.7 million in unrestricted cash, cash equivalents and marketable securities at March 31, 2026. According to the company, that compares to $14.9 million at December 31, 2025, reflecting an increase in reported liquidity.

Did LPCN 1154 meet the primary endpoint in the Phase 3 PPD trial?

No, LPCN 1154 did not meet the trial's primary endpoint for HAM-D reduction at hour 60 in the full analysis set. According to the company, the primary endpoint was not met, though safety and subgroup signals were reported.

What safety and subgroup findings did Lipocine report for LPCN 1154 (LPCN)?

Lipocine reported LPCN 1154 was well tolerated with no treatment-related serious adverse events or excessive sedation. According to the company, a post hoc subgroup with psychiatric history showed statistically significant HAM-D improvements.

What is Lipocine's near-term regulatory plan for LPCN 1154 (LPCN)?

The company has applied for breakthrough therapy and fast track designations for LPCN 1154 and is awaiting FDA feedback. According to the company, it is evaluating next steps including possible validation studies in the psychiatric-history subgroup.

How did Lipocine's revenue and expenses perform in Q1 2026 (LPCN)?

Royalty revenue from TLANDO was $119,000 in Q1 2026; the company reported a net loss of $3.7M. According to the company, R&D rose to $2.8M, driven by LPCN 1154 clinical costs.